Gilead to Acquire Arcellx in $7.8B Cell Therapy Deal
February 24, 2026 — Foster City, CA & Redwood City, CA:Gilead Sciences, Inc. (Nasdaq: GILD) today revealed a definitive...
cell therapy innovation
Advertisement
First Patient Dosed in CAR-T Trial Using Synecta T1 Nanoparticles
PHILADELPHIA, September 3, 2025 — The first patient has been dosed in a clinical trial evaluating Synecta™ T1 cell-derived...
Advertisement
